Literature DB >> 28634697

In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls.

Angelo Fassio1, Luca Idolazzi2, Ombretta Viapiana2, Camilla Benini2, Elisabetta Vantaggiato2, Francesco Bertoldo3, Maurizio Rossini2, Davide Gatti2.   

Abstract

Psoriatic Arthritis (PsA) is characterized by bone erosive damage often associated with exuberant bone formation especially in enthesial sites. Dkk-1 and sclerostin are the main inhibitors of the WNT/β-catenin signaling pathway and play a key role in the regulation of both bone formation and resorption. We performed this study in order to compare the serum levels of the WNT-pathway regulators along with bone turnover markers (BTM) and parathyroid hormone (PTH) between three different groups: one group of female patients affected by PsA, one group of female patients affected by rheumatoid arthritis (RA), and healthy female controls (HC). This is a cross-sectional study including 33 patients with PsA classified with the CASPAR criteria, 35 HC, and 28 patients with RA classified with the ACR/EULAR 2010 criteria. Intact N-propeptide of type I collagen (PINP), C-terminal telopeptide of type I collagen (CTX-I), Dickkopf-related-protein 1 (Dkk-1), sclerostin, PTH, and 25OH-vitamin D serum levels were dosed. The PsA group showed significantly lower Dkk-1 levels when compared to the HC and RA groups. Dkk-1 in the RA group was significantly higher than HC. A similar trend was documented for PTH. In the PsA group, CTX-I was found to be lower than in both the RA and HC groups. This study demonstrated for the first time that Dkk-1 levels in PsA are lower than HC, in contrast with RA, in which they are increased. These results might contribute to explain the different bone involvement of the two different diseases.

Entities:  

Keywords:  Bone turnover markers; Dkk-1; Psoriatic arthritis; Rheumatoid arthritis; Sclerostin; WNT

Mesh:

Substances:

Year:  2017        PMID: 28634697     DOI: 10.1007/s10067-017-3734-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  33 in total

1.  Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation.

Authors:  Donald A Glass; Peter Bialek; Jong Deok Ahn; Michael Starbuck; Millan S Patel; Hans Clevers; Mark M Taketo; Fanxin Long; Andrew P McMahon; Richard A Lang; Gerard Karsenty
Journal:  Dev Cell       Date:  2005-05       Impact factor: 12.270

2.  The natural disease course of ankylosing spondylitis.

Authors:  S Carette; D Graham; H Little; J Rubenstein; P Rosen
Journal:  Arthritis Rheum       Date:  1983-02

3.  The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1.

Authors:  Davide Gatti; Ombretta Viapiana; Luca Idolazzi; Elena Fracassi; Maurizio Rossini; Silvano Adami
Journal:  J Clin Endocrinol Metab       Date:  2011-03-02       Impact factor: 5.958

4.  In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density.

Authors:  Maurizio Rossini; Ombretta Viapiana; Silvano Adami; Elena Fracassi; Luca Idolazzi; Carmela Dartizio; Maria Rosaria Povino; Giovanni Orsolini; Davide Gatti
Journal:  Clin Exp Rheumatol       Date:  2014-12-01       Impact factor: 4.473

Review 5.  Involvement of WNT/β-catenin signaling in the treatment of osteoporosis.

Authors:  Maurizio Rossini; Davide Gatti; Silvano Adami
Journal:  Calcif Tissue Int       Date:  2013-06-11       Impact factor: 4.333

6.  Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion.

Authors:  Nicola Dalbeth; Bregina Pool; Timothy Smith; Karen E Callon; Maria Lobo; William J Taylor; Peter B Jones; Jillian Cornish; Fiona M McQueen
Journal:  Arthritis Res Ther       Date:  2010-08-26       Impact factor: 5.156

Review 7.  Wnt signaling pathway in rheumatoid arthritis, with special emphasis on the different roles in synovial inflammation and bone remodeling.

Authors:  Cheng-gui Miao; Ying-ying Yang; Xu He; Xiao-feng Li; Cheng Huang; Yan Huang; Lei Zhang; Xiong-Wen Lv; Yong Jin; Jun Li
Journal:  Cell Signal       Date:  2013-04-17       Impact factor: 4.315

8.  Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis.

Authors:  Heiner Appel; Gisela Ruiz-Heiland; Joachim Listing; Jochen Zwerina; Martin Herrmann; Ruediger Mueller; Hildrun Haibel; Xenofon Baraliakos; Axel Hempfing; Martin Rudwaleit; Joachim Sieper; Georg Schett
Journal:  Arthritis Rheum       Date:  2009-11

9.  Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score.

Authors:  Monika M Schoels; Daniel Aletaha; Farideh Alasti; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2015-08-12       Impact factor: 19.103

10.  Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis.

Authors:  Dimitrios Daoussis; Stamatis-Nick C Liossis; Elena E Solomou; Anastasia Tsanaktsi; Konstadina Bounia; Maria Karampetsou; Georgios Yiannopoulos; Andrew P Andonopoulos
Journal:  Arthritis Rheum       Date:  2010-01
View more
  11 in total

1.  Increased circulating sclerostin levels in rheumatoid arthritis patients: an updated meta-analysis.

Authors:  Yan-Mei Mao; Tao Liao; Qian-Ling Ye; Guo-Cui Wu; Qin Zhang; Sha-Sha Tao; Chan-Na Zhao; Qian Wu; Yi-Lin Dan; Hai-Feng Pan; Dong-Qing Ye
Journal:  Z Rheumatol       Date:  2021-09-20       Impact factor: 1.372

Review 2.  Altered Bone Remodeling in Psoriatic Disease: New Insights and Future Directions.

Authors:  Ananta Paine; Christopher Ritchlin
Journal:  Calcif Tissue Int       Date:  2018-01-12       Impact factor: 4.333

3.  Parathyroid hormone is a determinant of serum Dickkopf-1 levels in ankylosing spondylitis.

Authors:  Giovanni Orsolini; Giovanni Adami; Maurizio Rossini; Francesco Ghellere; Cristian Caimmi; Angelo Fassio; Luca Idolazzi; Davide Gatti; Ombretta Viapiana
Journal:  Clin Rheumatol       Date:  2018-07-11       Impact factor: 2.980

Review 4.  Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases.

Authors:  Harjit P Bhattoa; Zoltán Szekanecz; Boglárka Soós; Ágnes Szentpétery; Hennie G Raterman; Willem F Lems
Journal:  Nat Rev Rheumatol       Date:  2022-03-10       Impact factor: 20.543

Review 5.  The role of IL-23 receptor signaling in inflammation-mediated erosive autoimmune arthritis and bone remodeling.

Authors:  Wida Razawy; Marjolein van Driel; Erik Lubberts
Journal:  Eur J Immunol       Date:  2018-01-15       Impact factor: 5.532

Review 6.  Osteoimmunology of Bone Loss in Inflammatory Rheumatic Diseases.

Authors:  Fabienne Coury; Olivier Peyruchaud; Irma Machuca-Gayet
Journal:  Front Immunol       Date:  2019-04-03       Impact factor: 7.561

Review 7.  A Jack of All Trades: Impact of Glucocorticoids on Cellular Cross-Talk in Osteoimmunology.

Authors:  Mubashir Ahmad; Yasmine Hachemi; Kevin Paxian; Florian Mengele; Mascha Koenen; Jan Tuckermann
Journal:  Front Immunol       Date:  2019-10-17       Impact factor: 7.561

8.  Diffuse Idiopathic Skeletal Hyperostosis (DISH) in Type 2 Diabetes: A New Imaging Possibility and a New Biomarker.

Authors:  Angelo Fassio; Giovanni Adami; Luca Idolazzi; Alessandro Giollo; Ombretta Viapiana; Emma Bosco; Riccardo Negrelli; Elena Sani; Damiano Sandri; Alessandro Mantovani; Giovanni Targher; Maurizio Rossini; Davide Gatti
Journal:  Calcif Tissue Int       Date:  2020-10-12       Impact factor: 4.333

9.  Role of Secreted Frizzled-Related Protein 1 and Tumor Necrosis Factor-α (TNF-α) in Bone Loss of Patients with Rheumatoid Arthritis.

Authors:  Andi Raga Ginting; Rudy Hidayat; Sumariyono Sumariyono; Sukamto Koesnoe
Journal:  Int J Rheumatol       Date:  2020-03-01

Review 10.  Recent Advances in Imaging for Diagnosis, Monitoring, and Prognosis of Psoriatic Arthritis.

Authors:  Angelo Fassio; Peter Matzneller; Luca Idolazzi
Journal:  Front Med (Lausanne)       Date:  2020-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.